Abstract
To the Editor: I am writing on behalf of the Pharmaceutical Research and Manufacturers of America (PhRMA) in response to the Editorial by Dr Fontanarosa and colleagues1 that discusses a policy that represents a change at JAMA. This change is reflected in the current JAMA Instructions for Authors2: